Forbion's Billion-Dollar Sale to Johnson & Johnson: A Landmark Achievement in Biotech Innovation
May 31, 2024, 3:37 pm
Location: Switzerland, Zurich, Wädenswil
Employees: 51-200
Founded date: 2011
Total raised: $1.4B
The recent announcement of Forbion's sale of Yellow Jersey Therapeutics to Johnson & Johnson for a staggering $1.25 billion has sent shockwaves through the biotech industry. This monumental deal, which includes the acquisition of rights to NM26, a revolutionary bi-specific antibody designed for the treatment of atopic dermatitis, has captured the attention of industry insiders and investors alike.
NM26, developed by Numab using its cutting-edge MATCH technology, targets IL-4Rα and IL-31, offering a glimmer of hope for individuals grappling with the debilitating effects of atopic dermatitis. Forbion's unwavering commitment to investing in groundbreaking biotechnology in Europe is clearly demonstrated through this strategic partnership with J&J.
The sale of Yellow Jersey Therapeutics to Johnson & Johnson not only signifies a significant financial milestone for Forbion but also underscores the potential of Numab's proprietary MATCH technology platform in driving innovation in the biotech space. This billion-dollar transaction serves as a shining example of Forbion's dedication to fostering and supporting pioneering advancements in the biotech sector.
The acquisition of Yellow Jersey Therapeutics by Johnson & Johnson is a testament to the transformative power of collaboration and innovation in the field of biotechnology. This landmark deal is poised to reshape the landscape of atopic dermatitis treatment and pave the way for a new era of therapeutic possibilities. With Forbion at the helm of this groundbreaking sale, the future of biotech innovation looks brighter than ever.
NM26, developed by Numab using its cutting-edge MATCH technology, targets IL-4Rα and IL-31, offering a glimmer of hope for individuals grappling with the debilitating effects of atopic dermatitis. Forbion's unwavering commitment to investing in groundbreaking biotechnology in Europe is clearly demonstrated through this strategic partnership with J&J.
The sale of Yellow Jersey Therapeutics to Johnson & Johnson not only signifies a significant financial milestone for Forbion but also underscores the potential of Numab's proprietary MATCH technology platform in driving innovation in the biotech space. This billion-dollar transaction serves as a shining example of Forbion's dedication to fostering and supporting pioneering advancements in the biotech sector.
The acquisition of Yellow Jersey Therapeutics by Johnson & Johnson is a testament to the transformative power of collaboration and innovation in the field of biotechnology. This landmark deal is poised to reshape the landscape of atopic dermatitis treatment and pave the way for a new era of therapeutic possibilities. With Forbion at the helm of this groundbreaking sale, the future of biotech innovation looks brighter than ever.